GLPwatch
[GLP-1 agonists: an overview].
Med Monatsschr Pharm · 2013
Last updated 2026-05-28GLP-1 agonists are used to treat type 2 diabetes because they help with weight loss and have a low risk of causing dangerously low blood sugar. However, there are concerns about possible harmful effects on the pancreas, and more research is needed to understand their long-term safety.
AI summary of the abstract below.
| Journal | Med Monatsschr Pharm, 2013 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease |
Abstract
GLP-1 agonists have been widely used in the therapy of type 2 diabetes due to their beneficial effects regarding weight loss and low risk of hypoglycemia. However, some safety concerns have been raised in view of possible detrimental effects to the pancreas. The future place of GLP-1 agonist in diabetes therapy will be determined by the current safety evaluation and data from studies investigating long-term effects.
Verbatim abstract via PubMed 23898602 ↗